EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Primary cardiac sarcomas: A clinicopathologic study in a single institution with 25 years of experience with an emphasis on MDM2 expression and adjuvant therapy for prognosis

Haeyon Cho, In-Hye Song, Uiree Jo iD, Ji-Seon Jeong, Hyun Jung Koo, Dong Hyun Yang, Sung-Ho Jung, Joon Seon Song iD, Kyung-Ja Cho

Cancer Medicine · 2023

DOI: 10.1002/cam4.6303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Haeyon Cho und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Heart Neoplasms, Hemangiosarcoma, Sarcoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asan Institute for Life Sciences, Asan Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary cardiac sarcomas are rare and their clinicopathologic features are heterogeneous. Among them, particularly intimal sarcoma is a diagnostic challenge due to nonspecific histologic features. Recently, MDM2 amplification reported to be a characteristic genetic event in the intimal sarcoma. In this study, we aimed to identify the types and incidence of primary cardiac sarcomas that occurred over 25 years in tertiary medical institutions, and to find clinicopatholgical significance through reclassification of diagnoses using additional immunohistochemistry (IHC).

Methods

We reviewed the primary cardiac sarcoma cases between January 1993 and June 2018 at Asan Medical Center, South Korea, with their clinicopathologic findings, and reclassified the subtypes, especially using IHC for MDM2 and then, analyzed the significance of prognosis.

Results

Forty‐eight (6.8%) cases of a primary cardiac sarcoma were retrieved. The tumors most frequently involved the right atrium ( n = 25, 52.1%), and the most frequent tumor subtype was angiosarcoma ( n = 23, 47.9%). Seven cases (53.8%) were newly reclassified as an intimal sarcoma by IHC for MDM2. Twenty‐nine (60.4%) patients died of disease (mean, 19.8 months). Four patients underwent a heart transplantation and had a median survival of 26.8 months. This transplantation group tended to show good clinical outcomes in the earlier stages, but this was not statistically significant ( p = 0.318). MDM2 positive intimal sarcoma showed the better overall survival ( p = 0.003) than undifferentiated pleomorphic sarcoma. Adjuvant treatment is beneficial for patient survival ( p < 0.001), particularly in angiosarcoma ( p < 0.001), but not in intimal sarcoma ( p = 0.154).

Conclusion

Our study supports the use of adjuvant treatment in primary cardiac sarcoma, as it was associated with a significantly better overall survival rate. Further consideration of tumor histology may be important in determining the optimal use of adjuvant treatment for different types of sarcomas. Therefore, accurate diagnosis by MDM2 test is important condsidering patient's prognosis and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart NeoplasmsHemangiosarcomaSarcomaHumansCombined Modality TherapyPrognosisProto-Oncogene Proteins c-mdm2

Stichwörter der Autor:innen

MDM2cardiac sarcomaheart transplantationintimal sarcomasurvival

Substanzen

MDM2 protein, humanProto-Oncogene Proteins c-mdm2

Autor:innen und Institutionen

  • Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Department of Thoracic and Cardiovascular Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

ORCID-Profile: Uiree Jo, Joon Seon Song

Förderung

  • Asan Institute for Life Sciences, Asan Medical Center

Zitieren

APA

Cho, H., Song, I. H., Jo, U., Jeong, J. S., Koo, H. J., Yang, D. H., Jung, S. H., Song, J. S., & Cho, K. J. (2023). Primary cardiac sarcomas: A clinicopathologic study in a single institution with 25 years of experience with an emphasis on MDM2 expression and adjuvant therapy for prognosis. Cancer Medicine. https://doi.org/10.1002/cam4.6303

Vancouver

Cho H, Song IH, Jo U, Jeong JS, Koo HJ, Yang DH, et al. Primary cardiac sarcomas: A clinicopathologic study in a single institution with 25 years of experience with an emphasis on MDM2 expression and adjuvant therapy for prognosis. Cancer Medicine. 2023. doi:10.1002/cam4.6303

BibTeX
@article{Cho2023,
  author = {Cho, Haeyon and Song, In-Hye and Jo, Uiree and Jeong, Ji-Seon and Koo, Hyun Jung and Yang, Dong Hyun and Jung, Sung-Ho and Song, Joon Seon and Cho, Kyung-Ja},
  title = {Primary cardiac sarcomas: A clinicopathologic study in a single institution with 25 years of experience with an emphasis on MDM2 expression and adjuvant therapy for prognosis},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6303}
}
Kostenlos starten →